Handbook_Volume III

71 1. Aspetti Generali [25] Giralt S, Stadtmauer F, Harousseau J, et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (ADM 3100). Leukemia 2009 (23): 1904-12 [26] Bensinger W , Appelbaum F, Rowley S et al. Factors that influence collection aand engraftment of autologous peripheral-blood stem cells. J Clin Oncol.1995;13(10):2547-55 [27] Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol. 2000;18(6):1360-77 [28] Saraceni F, Shem-Tov N, Olivieri A, Nagler A. Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective. Bone Marrow Transplant 2015; 50(7): 886-91 [29] Laszlo D. Educational session on New Challenges in mobilization – biosimilars. EBMT Meeting, Milano 2014 [30] Holig K. G-CSF in healthy allogeneic stem cell donors. Transfus Med Hemother 2013; 40(4); 225-235 [31] Kong J, Hu Y, Shim H, et al. Analysis of factors associated with successful allogeneic peripheral blood stem cell collection in healthy donors. Transfus Aphere Sci 2020; 59(2): 102679 [32] Bailen R, Perez-Corral A, Pascual C, et al. Factors predicting peripheral blood progenitor cell mobilization in healty donors in the era of related alternative donors. Experience from a single center. J Clin Apher 2019; 34(4): 373-80 [33] Martino M, Gori M, Pitino A. et al. Basal Cd34+ cell count predicts peripheral blood stem cell mobilization in healthy donors after administration of granulocyte colony-stimulating factor: a longitudinal, prospective, observational, single-center, cohort study. Biol Blood Marrow Transplant. 2017; 23(7):1215-20 [34] procedura operativa GITMO “Gestione del donatore MUD di CSE periferiche non mobilizzante” (10/11/2016) [35] Moog R. Apheresis techniques for collection of peripheral blood progenitor cells. Transfusion and Apheresis Science 2004; 31: 207-220 [36] O’Leary M F, Dunbar N M, Kim H C, et al. Venous Access for Hematopoietic Progenitor Cell Collection: An International Survey by the ASFA HPC Donor Subcommittee. J Clin Apheresis 2016(31): 529-34 [37] Caime A, Piredda A , Lucchetti B, et al. Midline catheter as effective device in healthy allogeneic donors and patients without an adequate peripheral venous access for HPC collection by apheresis: Preliminary experience at IEO Transfusion and Apheresis Science 2020; 59 (3); 1027-40 [38] Novel use of a midline catheter for therapeutic and donor apheresis in children and adults Colleen Casacchia | Maria Lozano | John Schomberg | Jennifer Barrows | Tamara Salcedo | Geetha Puthenveetil J Clin Apher. 2021;36:711–718 [39] Donmez A, Arik B, Tombuloglu M. et al. Risk factors for adverse events during collection of peripheral blood stem cells. Transfus Apher Sci 2011; 45(1): 13-16 [40] Buchta C, Macher M, Bieglmayer C, et al. Reduction of adverse citrate reactions during autologous large-volume PBPC apheresis by continuous infusion of calcium-gluconate. Transfusion 2003; 43(11): 1615-21pact on unrelated hematopoietic stem cell transplantation outcome. Hum Immunol. 2020;Jan;81(1):12-17 [10] Gertz M, Kumar S, Lacy M, et al. Comparison of high-dose CY and growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant 2009; 43(8): 619-25 [11] Laszlo D, Marcacci GP, Martino M, et al. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: an Italian explorative cost analysis. Transfus Apher Sci. 2020 Oct;59(5): 102819 [12] Kotasek D, Shepherd K, Sage R, et al. Factors affecting blood stem cell collection following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9(1): 11-7 [13] Jantunen E, Putkonen M, Nousiainen T, et al. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilization in patients with multiple myeloma. Bone Marrow Transplant 2003; 31(5): 347-51 [14] Lin TL, Wang PN, Kuo MC, et al., Cyclophosphamide Plus Granulocyte-Colony Stimulating Factor for Hematopoietic Stem Cell Mobilization in Patients With Multiple Myeloma. J Clin Apher 2016, 31(5): 423-8 [15] Afifi S, Adel NG, Devlin S, et al. Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study. Bone Marrow Transplant 2016, 51(4): 546-52 [16] Oyekunle A, Shumilov E, Kostrewa P et al. Chemotherapy-Based Stem Cell Mobilization Does Not Result in Significant Paraprotein Reduction in Myeloma Patients in the Era of Novel Induction Regimens. Biol Blood Marrow Transplan 2018, 24(2): 276-81 [17] Lazzaro C, Castagna C, Lanza F, et al. Chemotherapy-based versus chemotherapy-free stem cell mobilization (+/- plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis. Bone Marrow Transplant 2021; 56(8): 1876-87 [18] Piccirillo N, Vacca M, Lanti A, et al. Poor mobilizer: a retrospective study on proven and predicted incidence according to GITMO criteria. Transfus Apher Sci 2012; 47(2): 217-21 [19] Kotasek D, Shepherd KM, Sage RE, et al. Factors affecting blood stem cell collection following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9(1):11-17 [20] Olivieri A, Marchetti M, Lemoli R, et al. Proposed definition of “poor mobilizer” in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo Italiano Trapianto di Midollo Osseo. Bone Marrow Transplant 2011; 1-10 [21] Wuchter P, Ran D, Bruckner T et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010; 16:490-9 [22] Jantunen E and Lemoli M. Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept. Transfusion 2012; 52(4): 906-14 [23] Ketterer N, Salles G, Raba M et al. High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998, 91(9): 3148-55 [24] Schots R, Van Riet I, Damiaens S, et al. The absolute number of circulating CD34+ cells predicts the number of hematopoietic stem cells that can be collected by apheresis. Bone Marrow Transplant 1996; 17(4): 509-515